IONS Ionis Pharmaceuticals, Inc.

48.09
+0  (0%)
Previous Close 48.09
Open 49.51
Price To book 41.71
Market Cap 5.83B
Shares 121,202,000
Volume 1,713,943
Short Ratio 6.84
Av. Daily Volume 2,470,530

SEC filingsSee all SEC filings

  1. 8-K - Current report 17518153
  2. 8-K - Current report 17514752
  3. 8-K - Current report 162062185
  4. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 162045493
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 161984129

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 interim data released November 2016.
IONIS-ANGPTL3-LRx
Cardiovascular disease
Phase 1/2 ongoing
IONIS-DMPK-2.5Rx
Myotonic Dystrophy Type 1 (DM1)
Phase 3 to be completed in 1H 2017.
IONIS-TTRRx
NEURO-TTR - familial amyloid polyneuropathy (FAP).
Approved December 23, 2016.
SPINRAZA - Nusinersen
Spinal muscular atrophy (SMA)
Phase 2 data released November 2016.
IONIS-FXIRx
End-stage renal disease
Phase 3 enrolment completed
Volanesorsen - APROACH
Familial chylomicronemia syndrome (FCS)
Phase 2 data released 3Q 2015
IONIS-APO(a)Rx
High lipoprotein(a), or Lp(a)
Phase 2 data released January 4, 2016.
IONIS-GCGRRx
Type 2 diabetes
Phase 3 initiated November 2015
Volanesorsen
Partial lipodystrophy rapidly
Phase 2 released Feb 2015. Achieved statistically significant results but data released was as of 36 weeks rather than 27 weeks for the primary endpoint
IONIS-PTP1BRx
Type 2 diabetes
Phase 3 initiated November 2015
Volanesorsen
Familial partial lipodystrophy (FPL)
Partner GSK announced May 2016 decision not to be proceed with Phase 3 outcome trial
IONIS-TTRRx
CARDIO-TTR - Cardiomyopathy form of TTR amyloidosis.

Latest News

  1. Biogen Says Spinraza Drug Did Well In Phase 3 Trial
  2. Is Biogen's Stock Ready to Heat Up After a Forgettable 2016?
  3. Ionis Has High Hopes for Heart Drug Volanesorsen
  4. Why Ionis Pharmaceuticals Shares Fell by 22.8% in 2016
  5. New Data Show SPINRAZA™ (nusinersen) Significantly Reduces Risk of Death or Permanent Ventilation in Infantile-Onset Spinal Muscular Atrophy
  6. New Data Show SPINRAZA™ (nusinersen) Significantly Reduces Risk of Death or Permanent Ventilation in Infantile-Onset Spinal Muscular Atrophy
  7. Biotech Investors 'Spooked' After Trump's Comments, JMP's King Says
  8. The 1 Biotech Stock I Want to Own in 2017
  9. Ionis’ Stocks Surge After Novartis Deal (IONS)
  10. Company News for January 11, 2017
  11. 3 Big Reasons (and 8 Smaller Ones) to Buy Ionis Pharmaceuticals Stock
  12. IONIS PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity
  13. Biotech Industry Off to a Strong Start in 2017 Latest Reports on Seattle Genetics and Ionis Pharmaceuticals
  14. Ionis, Novartis Ink Deal to Focus on Cardiovascular Treatments
  15. Blog Coverage Novartis Joins Hands with Ionis Pharma For Cardiovascular Treatment Solutions
  16. IONIS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
  17. Ionis Pharmaceuticals Significantly Improves Upon 2016 Financial Guidance
  18. Ionis Pharma Stock Bounds On $100 Million Novartis Investment
  19. Ionis Pharmaceuticals Significantly Improves Upon 2016 Financial Guidance
  20. Ionis, Novartis Ink Collaboration Worth Up to $1.6B Plus Royalties

SEC Filings

  1. 8-K - Current report 17518153
  2. 8-K - Current report 17514752
  3. 8-K - Current report 162062185
  4. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 162045493
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 161984129
  6. 8-K - Current report 161982831
  7. CT ORDER - Confidential treatment order 161918560
  8. CT ORDER - Confidential treatment order 161917619
  9. 8-K - Current report 161899395
  10. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 161878455